Mizuho Maintains Outperform on Revolution Medicines, Raises Price Target to $215
Revolution Medicines
Revolution Medicines RVMD | 0.00 |
Mizuho analyst Joseph Catanzaro maintains Revolution Medicines (NASDAQ:
RVMD) with a Outperform and raises the price target from $185 to $215.
